Tirzepatide is often grouped with the GLP-1 drugs, but it is built differently, and that matters when you design a pharmacokinetic (PK) assay. It activates two receptors, GIP and GLP-1, from a single peptide. It travels bound to albumin. And its dose escalates across a six-fold range. Each of those facts changes what a good assay has to do.
This post covers what makes tirzepatide distinctive, the six assay questions worth settling before you start, and how ELISA and LC-MS/MS fit.
Key points
- Tirzepatide is 99% albumin-bound with a half-life of 5–6 days, so decide early whether you are measuring total drug.
- Dose escalation from 2.5 mg to 15 mg means your assay range has to cover the whole titration, or your dilution plan has to.
- Specificity against other GLP-1 agonists and endogenous GIP and GLP-1 is not optional to check.
- Long studies need lot-to-lot consistency, because the kit you start with is not always the kit you finish with.
What makes tirzepatide different?
Tirzepatide is a synthetic peptide of 39 amino acids with a C20 fatty diacid moiety. That moiety drives high-affinity albumin binding, which extends its half-life enough for once-weekly dosing. The key PK parameters from the prescribing information:
Source: Zepbound prescribing information.
Six assay considerations
Decide what you are measuring: total or free drug
With 99% of tirzepatide bound to albumin, most immunoassays report total drug. That is usually what PK studies need, but state it in your method and make sure your sample handling doesn’t shift the bound fraction.
Plan for the dose range
Tirzepatide is titrated from 2.5 mg up to 15 mg, so concentrations across a study span a wide range, and steady state takes about four weeks to reach. An assay with a broad working range reduces re-runs. Where it doesn’t cover everything, build your dilution scheme before the first sample arrives.
Check specificity properly
Endogenous GIP and GLP-1 share sequence features with tirzepatide, and patients in switching or combination studies may carry other GLP-1 agonists. Ask any assay supplier for cross-reactivity data against those molecules, and test your own matrix. This matters in practice: some class-specific antibodies read several agonists at similar levels.
The KRIBIOLISA™ Tirzepatide ELISA was evaluated against Exenatide and Semaglutide. At 500 ng/mL, the remaining assay signal was 37.4% for Tirzepatide and 52.6% for Exenatide; at 1,000 ng/mL, it was 19.8% and 36.6%, respectively. Semaglutide showed minimal to no significant signal reduction, indicating minimal to no cross-reactivity under the tested conditions.
Test with the material you will actually use
Innovator product, biosimilar and in-house reference standards can differ in formulation, and an assay should quantify them consistently. If your programme compares products, include each in the validation.
Respect peptide handling
Peptides adsorb to surfaces, and repeated freeze-thaw can change recovery. Use low-binding labware, standardise handling, and test spike recovery and dilution linearity in your own matrix, for parallelism as well as accuracy.
Expect lot changes in a long study
Weekly dosing means studies run for months. If the kit lot changes mid-study, lot-to-lot variation becomes part of your data. Ask for multi-lot data before you commit.
ELISA or LC-MS/MS?
Both suit tirzepatide, for different reasons.
ELISA needs a plate reader, runs many samples in one go, and costs little per sample. It is a practical choice for routine PK, comparability and batch testing, with the method validated in your own matrix.
LC-MS/MS identifies the molecule by mass. That makes it the reference for distinguishing closely related agonists and reaching the lowest concentrations, at the price of an instrument, an experienced operator and a queue.
Many labs use ELISA for volume and LC-MS/MS to confirm key results. (For a detailed comparison, see our post on measuring semaglutide in serum.)
Where the Krishgen tirzepatide ELISA fits
We developed the KRIBIOLISA Tirzepatide (Mounjaro) ELISA (KOD1027) as the world’s first commercially available tirzepatide ELISA. Data presented at the AAI 2025 meeting show:
- Working range: 31.3 to 4,000 ng/mL, with an IC50 of about 345 ng/mL.
- Lot-to-lot consistency: across four lots, CV of 5% or less over most of the range.
- Precision: below 15% intra-assay and below 18% inter-assay.
- Reference materials: tested against Mounjaro and a tirzepatide biosimilar.
Each of those answers one of the questions above: range, consistency, and tested material. The kit is intended for the quantitative determination of Tirzepatide in human serum and plasma. Samples should be diluted 1:1000 before testing.
Questions people ask
Can I use an ELISA for tirzepatide PK?
Yes, provided the assay range fits your samples after dilution and you validate in your own matrix. Confirm that your expected concentrations fall inside the range.
Does it measure free or total drug?
Immunoassays typically report total drug. Talk to our application team about how KOD1027 performs with albumin-bound tirzepatide in your matrix.
Can I try the kit first?
Authorised distributors can offer eligible customers free validation kits from stock. Contact us.
For research use only.
Talk to our application team
Tell us your matrix, dose range and study length, and we will suggest a dilution scheme and validation plan.
References
- Eli Lilly and Company. Zepbound (tirzepatide) prescribing information, clinical pharmacology.
- Krishgen Biosystems. Tirzepatide ELISA (KOD1027) poster, AAI 2025.
- ICH M10: Bioanalytical Method Validation and Study Sample Analysis.
